COLLABORATION TO DEVELOP EVIDENCE-BASED STRATEGIES TO HELP IMPROVE OSTEOARTHRITIS MANAGEMENT Haleon and University of Sydney launch 5-Year fellowship to research efficacy of dietary supplements
SEGMENT
Filmed in Sydney and online | February 2025
INTERVIEWS
Professor David Hunter,
Florance and Cope Chair of Rheumatology
Co-Director Sydney Musculoskeletal Health Flagship,
University of Sydney
Dr Bincy Thampi,
Medical & Scientific Affairs Lead
Haleon ANZ
Osteoarthritis is a leading cause of disability affecting over 2 million Australians, according to Australian Institute of Health and Welfare report on Chronic musculoskeletal conditions (2024) and 595 million people globally, according to BD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020. It represents a significant public health burden that diminishes quality of life among ageing populations.
Consumer healthcare company Haleon is sponsoring a five-year named fellowship program at the University of Sydney that will investigate the therapeutic role of supplements in managing osteoarthritis symptoms and digital health technologies that improve mobility.
The fellowship will fund a postdoctoral researcher to work under the guidance of world leading osteoarthritis expert, rheumatologist and researcher Professor David Hunter.
Australian Health Journal spoke with Professor Hunter who said the research collaboration represents a shared focus and investment in improving osteoarthritis management: “This is a disabling disease that has a huge impact on the people affected.”
“A collaborative effort between researchers and manufacturers will drive innovation and hopefully improve the lives of those impacted by this devastating disease. Use of supplements and natural ingredients in managing osteoarthritis is an exciting area with a lot of potential. I’m not aware of any other long-term, five-year projects of this nature that has osteoarthritis as its focus,” said Hunter.
Haleon and the University of Sydney have a shared goal of finding better management strategies for osteoarthritis and developing better outcomes for the people affected.
Dr Bincy Thampi, Medical & Scientific Affairs Lead at Haleon ANZ, also spoke with Australian Health Journal and says, “Haleon has a strong commitment to scientific research that drives innovative self-care and improves consumer health outcomes.”
“This partnership illustrates Haleon’s commitment to advancing trusted science for our products to better everyday health and we’re excited to see where this partnership with University of Sydney leads,” said Dr Thampi.
-
The desire for primary care nurses to do more, be recognised and valued for the work they do
Denise Lyons is a highly experienced nurse with over 40 years in the profession, including more than 25 years dedicated to primary care. She earned her Bachelor of Science in Nursing in the United States in 1985 and, in 2012, became an endorsed Nurse Practitioner in Australia. Currently, she serves as a primary care Nurse Practitioner in General Practice in Newcastle, where she is committed to delivering high-quality, patient-centred care that improves the health and wellbeing of her community.
-
A 40-Year Journey: Insights from Tasmania’s Chief Nurse & Midwife
Reflecting on her nursing journey on the Tasmanian Health website on International Nurses Day 2025, Chief Nurse and Midwife, Francine Douce, has seen plenty of change since the start of her nursing and midwifery career, 42 years ago.
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.
